A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Fierce Pharma

Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Eli Lilly and Company (LLY) announces results from phase 3 BRUIN CLL-314 trial evaluating Jaypirca versus Imbruvica

Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company ...

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in …

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...
Fierce Pharma

ASH: Lilly oncology chief sees sweet spot for Jaypirca in 2nd-line CLL despite 1st-line trial wins

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...
BioPharma Dive

At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

Structure Therapeutics details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron that just showed positive results from a ...

Obesity biotechs’ gains hit shares of Eli Lilly, Novo Nordisk

Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.